Lumasiran for treating primary hyperoxaluria type 1 (HST25)

Clinical guideline · Tier 1, UK official · UK · 2022-11-16

Current — checked with the publisher on 2026-09-02

https://www.nice.org.uk/guidance/hst25

What this platform has drawn from it — 1 claim

NICE states that in primary hyperoxaluria type 1 a genetic mutation causes the liver to produce excess oxalate, which builds up in the kidneys and urinary tract. Section 3 Committee discussion, 'Primary hyperoxaluria type 1'
read on Gene therapy and the liver

How this record was checked, and what is doubtful about it

Held for ONE sentence, in which NICE states in its own words that the genetic fault is in the liver and the damage falls on the kidney. That sentence is the clearest statement in the whole phase of the distinction this concept exists to make.

Verification: verified · last accessed 2026-09-02 · status checked against https://www.nice.org.uk/guidance/hst25